Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:JRSHNASDAQ:MGOLNASDAQ:PMNTNASDAQ:SILO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJRSHJerash Holdings (US)$3.13-0.6%$3.10$2.68▼$4.17$38.48M1.0231,547 shs37,032 shsMGOLMGO Global$0.31-33.8%$0.31$0.10▼$17.30$894K7.2623.67 million shs106.10 million shsPMNTPerfect Moment$0.60-9.1%$0.87$0.51▼$2.94$9.86M-3.0667,391 shs19,194 shsSILOSilo Pharma$0.58-9.2%$0.81$0.41▼$4.50$2.61M0.012.36 million shs6.20 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJRSHJerash Holdings (US)0.00%-5.12%+4.13%-14.86%+3.28%MGOLMGO Global0.00%0.00%0.00%0.00%-93.45%PMNTPerfect Moment-2.46%+3.15%-21.56%-37.62%-77.02%SILOSilo Pharma+12.08%+35.54%-21.57%-50.77%-46.67%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJRSHJerash Holdings (US)N/AN/AN/AN/AN/AN/AN/AN/AMGOLMGO GlobalN/AN/AN/AN/AN/AN/AN/AN/APMNTPerfect Moment2.9417 of 5 stars3.55.00.00.03.01.70.0SILOSilo Pharma0.4887 of 5 stars0.01.00.00.02.61.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJRSHJerash Holdings (US) 0.00N/AN/AN/AMGOLMGO Global 0.00N/AN/AN/APMNTPerfect Moment 3.00Buy$6.00908.40% UpsideSILOSilo Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJRSHJerash Holdings (US)$138.14M0.28$0.40 per share7.86$5.14 per share0.61MGOLMGO Global$5.20M0.17N/AN/A$0.64 per share0.48PMNTPerfect Moment$21.31M0.46N/AN/A$0.05 per share11.90SILOSilo Pharma$72.10K36.14N/AN/A$2.14 per share0.27Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJRSHJerash Holdings (US)-$2.01M-$0.31N/A∞N/A-2.73%-5.97%-4.78%6/26/2025 (Estimated)MGOLMGO Global-$7.14M-$4.57N/A∞N/A-142.93%-412.85%-291.72%N/APMNTPerfect Moment-$8.72M-$1.30N/A∞N/A-67.38%-513.83%-119.38%7/7/2025 (Estimated)SILOSilo Pharma-$3.70M-$1.17N/A∞N/A-5,255.05%-61.38%-47.49%8/11/2025 (Estimated)Latest PMNT, JRSH, SILO, and MGOL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/26/2025Q4 2025JRSHJerash Holdings (US)$0.04N/AN/AN/A$32.70 millionN/A5/9/2025Q1 2025SILOSilo PharmaN/A-$0.23N/A-$0.23N/A$0.02 million3/28/2025Q4 2024SILOSilo PharmaN/A-$0.41N/A-$0.41N/A$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJRSHJerash Holdings (US)$0.206.39%N/AN/A N/AMGOLMGO GlobalN/AN/AN/AN/AN/APMNTPerfect MomentN/AN/AN/AN/AN/ASILOSilo PharmaN/AN/AN/AN/AN/ALatest PMNT, JRSH, SILO, and MGOL DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/20/2025JRSHJerash Holdings (US)quarterly$0.056.3%5/30/20255/30/20256/6/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJRSHJerash Holdings (US)N/A3.131.96MGOLMGO GlobalN/A14.138.37PMNTPerfect MomentN/A1.010.70SILOSilo PharmaN/A7.917.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJRSHJerash Holdings (US)3.39%MGOLMGO Global1.05%PMNTPerfect Moment23.00%SILOSilo Pharma5.58%Insider OwnershipCompanyInsider OwnershipJRSHJerash Holdings (US)41.70%MGOLMGO Global12.60%PMNTPerfect MomentN/ASILOSilo Pharma4.37%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJRSHJerash Holdings (US)5,60012.30 million7.17 millionNot OptionableMGOLMGO Global72.90 million2.54 millionNot OptionablePMNTPerfect Moment3116.57 millionN/AN/ASILOSilo Pharma24.48 million4.29 millionNot OptionablePMNT, JRSH, SILO, and MGOL HeadlinesRecent News About These CompaniesSilo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve AssetJune 5 at 9:15 AM | globenewswire.comSilo Wellness to Relist as Born Defense, a National Security Investment Issuer Focused on Ending Forever Wars and Upholding the Just War DoctrineJune 2, 2025 | newsfilecorp.comSilo Pharma, Inc.: Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15May 23, 2025 | finanznachrichten.deSilo Pharma teams up with Resyca for IND-supporting intranasal drug-device study of PTSD drugMay 21, 2025 | msn.comSilo Pharma, Inc. Partners with Resyca BV for SPC-15 Drug-Device Study Aimed at PTSD TreatmentMay 21, 2025 | quiverquant.comSilo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15May 21, 2025 | globenewswire.comSilo Pharma, Inc.: Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15May 16, 2025 | finanznachrichten.deSilo Pharma Signs With Frontage Labs For FDA Requested Safety Study Of SPC-15May 16, 2025 | nasdaq.comSilo Pharma Announces Closing of $2 Million Public OfferingMay 16, 2025 | globenewswire.comSilo Pharma Retail Buzz Surges On FDA Toxicology Study Plans For PTSD TreatmentMay 16, 2025 | msn.comSilo Pharma, Inc. Prices Public Offering of 3,333,338 Shares with Associated WarrantsMay 15, 2025 | quiverquant.comSilo Pharma Announces Pricing of $2 Million Public OfferingMay 15, 2025 | globenewswire.comSilo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15May 14, 2025 | globenewswire.comSilo Pharma, Inc. Announces Agreement with Frontage Laboratories for SPC-15 Safety and Toxicology Study Targeting PTSD TreatmentMay 14, 2025 | quiverquant.comSilo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage LaboratoriesMay 14, 2025 | globenewswire.comCounterproposal to Swiss cost-cutting initiativeMay 12, 2025 | thepharmaletter.comSilo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia StudyApril 30, 2025 | finance.yahoo.comSilo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia StudyApril 30, 2025 | globenewswire.comSilo Pharma Files Patent Application for Alzheimer's Drug SPC-14 Targeting Novel Mechanism of ActionApril 29, 2025 | nasdaq.comSarasota company applies for Alzheimer's drug patentApril 29, 2025 | businessobserverfl.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMNT, JRSH, SILO, and MGOL Company DescriptionsJerash Holdings (US) NASDAQ:JRSH$3.13 -0.02 (-0.63%) Closing price 04:00 PM EasternExtended Trading$3.14 +0.01 (+0.32%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jerash Holdings (US), Inc., through its subsidiaries, manufactures and exports customized and ready-made sport and outerwear. The company offers t-shirts; jackets and pullover; pants and shorts; crew neck, polo shirts, and tank tops made from knitted fabric, as well as personal protective equipment. It serves various brand-name retailers in the United States, Hong Kong, Jordan, and internationally. The company was incorporated in 2016 and is headquartered in Fairfield, New Jersey.MGO Global NASDAQ:MGOL$0.31 -0.16 (-33.76%) Closing price 02/19/2025Extended Trading$0.31 0.00 (0.00%) As of 02/19/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MGO Global, Inc. operates as a lifestyle brand portfolio company. The company is involved in the fashion design, brand development and management, sourcing and manufacturing, licensing, IP protection, corporate finance, consumer engagement and experience, ecommerce, and retail sales and marketing activities related to the Messi brand. MGO Global, Inc. was founded in 2018 and is headquartered in Fort Lauderdale, Florida.Perfect Moment NASDAQ:PMNT$0.60 -0.06 (-9.15%) Closing price 03:19 PM EasternExtended Trading$0.60 +0.00 (+0.34%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perfect Moment Ltd., together with its subsidiaries, owns and operates a fashion brand that offers ski, surf, and activewear collections under the brand name of Perfect Moment. It offers skiwear, outerwear, swimwear and activewear for women, men, and children. The company sells its collections directly to customers through e-commerce and to wholesale accounts, as well as through other sales partnerships. Perfect Moment Ltd. was founded in 1984 and is based in London, the United Kingdom.Silo Pharma NASDAQ:SILO$0.58 -0.06 (-9.20%) Closing price 04:00 PM EasternExtended Trading$0.57 -0.02 (-2.60%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal MongoDB Affirms Outlook and Accelerates Stock Price Reversal Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? AT&T: Is This Telecom Giant a Buy or a Bye for Your Portfolio? Why Visa's Innovation Engine Keeps It a Top Portfolio Pick Is Meta Plotting a Stablecoin Comeback Years After Libra's Flop? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
